• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

MDA19 Inhibitor – MDA 19

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5764429

MBS5764429 is an inhibitor targeting MDA19. Also known as MDA 19. MDA 19 is a specific human CB2 receptor agonist (Ki: 43.3nM). More details

DISCONTINUED
Click here to view our similar product(s) OR click here to contact our technical support team for suitable replacement.
Product Documentation
PDF
Sample Manual Insert View PDF
PDF
Testing Data View PDF
PDF
Certificate of Analysis (COA) View PDF
PDF
QC Report View PDF
PDF
Material Safety Data Sheet View PDF
PDF
Technical Datasheet View PDF
PDF
Protocol View PDF

Product Overview

Product Name
MDA 19 (MDA19), Inhibitor
Full Product Name
MDA 19
Product Gene Name
Form/Format
Solid. Powder
Purity/Purification
98.00%
Preparation and Storage
Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent
Molecular Weight
349.43
Solubility
DMSO: 14mg/mL (40.07mM) Need ultrasonic
Water: Insoluble
(<1mg/ml refers to the product slightly soluble or insoluble)
Formula
C21H23N3O2
SMILES
CCCCCCN(c(cccc1)c1/C1=N/NC(c2ccccc2)=O)C1=O
CAS Number
1048973-47-2
In Vitro
MDA19 attenuated tactile allodynia produced by spinal nerve ligation or paclitaxel in a dose-related manner in rats and CB2(+/+) mice but not in CB2(-/-) mice, indicating that CB2 receptors mediated the effects of MDA19. MDA19 did not affect rat locomotor activity.

Product References and Citations for MDA19, inhibitor

Diaz, Philippe; Xu, Jijun; Astruc-Diaz, Fanny et al. Design and Synthesis of a Novel Series of N-Alkyl Isatin Acylhydrazone Derivatives that Act as Selective Cannabinoid Receptor 2 Agonists for the treatment,of Neuropathic Pain. J Med Chem
Diaz, Philippe; Xu, Jijun; Astruc-Diaz, Fanny et al. Design and Synthesis of a Novel Series of N-Alkyl Isatin Acylhydrazone Derivatives that Act as Selective Cannabinoid Receptor 2 Agonists for the treatment,of Neuropathic Pain. J Med Chem, 51 (16), 4932-47
Xu JJ, Diaz P, Astruc-Diaz F et al. Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment,of neuropathic pain. Anesth Analg. 2010 Jul;111(1):99-109.
Xu JJ, Diaz P, Astruc-Diaz F et al. Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment,of neuropathic pain. Anesth Analg. 2010 Jul;111(1):99-109.

Other Notes

Small volumes of MDA19, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Request a Quote

Please fill out the form below and our representative will get back to you shortly.

MBS000000
Contact Us

Please fill out the form below and our representative will get back to you shortly.

MBS000000